Bulletin: Verisk Analytics Inc. Ratings Unaffected By Bloodhound Technologies Inc. Acquisition Apr 11

  • ID: 1718279
  • April 2011
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) April 28, 2011--Standard & Poor's Ratings Services said today that its ratings on Jersey City, N.J.-based data and analytics provider Verisk Analytics Inc. are unaffected by its $82 million acquisition of Bloodhound Technologies Inc., a provider of claims editing services for health care payers. The acquisition was funded completely with cash on hand, and, in our view, the company's remaining cash balance is sufficient given the full availability under its $600 million revolver and good free cash flow. Furthermore, our ratings incorporate our expectation that Verisk's growth and diversification strategy will continue to entail acquisitions funded with a mix of cash and debt. Therefore, Standard & Poor's views the current cash funded acquisition as neutral...

Companies mentioned in this report are:
- Verisk Analytics Inc.

Action: Bulletin

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Verisk Analytics Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.